Latest guidance given with Q3 FY2026 results, 29 Oct 2026
| Measure | Period | Guidance | As stated |
|---|---|---|---|
| Revenue | FY2026 | $5.21B to $5.30B | Total net sales $5,210 - $5,300 million |
Source: the company's earnings release.
In its results release of 29 Oct 2026 (Q3 FY2026), Incyte gave 1 forecast in figures, among them revenue of $5.21B to $5.30B for FY2026.
Read from the company's earnings releases and outlook updates of the last two years. Each forecast is shown with the sentence or table row it was read from; what a release does not state in figures is not shown.
| Measure | Period | Guidance | As stated |
|---|---|---|---|
| Revenue | FY2026 | $5.21B to $5.30B | Total net sales $5,210 - $5,300 million |
Source: the company's earnings release.
The last range given before each period closed, how it moved between releases, and the figure then filed. A measure the company defines itself, or one not comparable with the filed figure, has no verdict.
| Measure | Period | Last guidance | Revisions | Delivered | Result |
|---|---|---|---|---|---|
| Revenue | FY2026 | $5.21B to $5.30B | Raised twice | — | To come |
Guidance said on earnings calls, every revision charted, and guidance set against the analysts' consensus.